PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123F61005Purpose of THIS modification IS to — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75A50122D00002. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Department of Health and Human Services (HHS)
Agency
Glaxosmithkline LLC
Recipient
Dec 31, 2027
PoP end
$171.6M
Obligated
541714
NAICS
AN12
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number75A50123F61005
Also listed as75A50122D00002-75A50123F61005
AgencyDepartment of Health and Human Services (HHS)
Awarding officeBarda - Aspr / Daappo / Barda Dcma
IncumbentGlaxosmithkline LLC
UEIFRHTPHMZMX47
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12
Parent IDIQ / IDV75A50122D00002
Place of performanceMARIETTA, PA
PoP end (current)Dec 31, 2027
Obligated$171.6M

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 A… is a federal award for Department of Health and Human Services (HHS) held by Glaxosmithkline LLC. Estimated value $171.6M ($171.6M obligated). Current period of performance ends Dec 31, 2027. Place of performance: MARIETTA, PA.

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 ADJUVANT FROM CONTRACT # W15QKN-20-C-0048 TO CONTRACT # 75A50122D00002 2. ADD FUNDING IN THE AMOUNT OF $1,038,708.00 FOR 33 BUL

Recompete timing

Public
● Expiring in 457 days

Current PoP ends Dec 31, 2027 (457 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Bonuses end Sept 30

Want the durability read on 75A50123F61005? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORI…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$493K
Oct 29, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$15.4M
Feb 21, 2027
75A50124F61010
THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVA…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$40.9M
May 21, 2027
75A50124F61012
THE PURPOSE OF THIS HHS TASK ORDER IS TO PROCURE SERVICES FOR THE STORAGE AND STABILITY OF…
Department of Health and Human Services (HHS) · GLAXOSMITHKLINE LLC
$14.0M
May 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50123F61005?

75A50123F61005 (Purpose of THIS modification IS to) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $171.6M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50123F61005?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50123F61005 to Glaxosmithkline LLC.

Who is the incumbent on 75A50123F61005?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does Glaxosmithkline LLC’s 75A50123F61005 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50123F61005? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50123F61005